Macrolides in Refractory Asthma

ottingham University0 个研究点目标入组 0 人开始时间: 2008年5月2日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•Non-smoking subjects aged 16 to 80 with refractory asthma, FEV1 >50% predicted and >1L and measurable airway responsiveness to methacholine challenge. Refractory asthma will be defined as an FEV1/FVC ratio less than 70% with evidence of poor asthma control in terms of regular night-time awakening (>2/week) or more than 4 puffs of relief medication/day (>twice/week) requiring repeated (2 or more per year) courses of oral corticosteroids despite treatment with high dose inhaled corticosteroids (=1000mg beclomethasone or equivalent) and treatment with, or a previous unsuccessful trial of, a long-acting beta-agonist or leukotriene antagonist.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Poor compliance with their usual asthma treatment as assessed by a review of primary care records, pregnancy, inadequate contraception or lactation, active smoking or smoking history in excess of 20 pack years, a clinical diagnosis of ABPA or significant bronchiectasis, other major co-morbidity including abnormal liver function tests or medication known to interact with azithromycin (aprepitant, atazanavir, atorvastatin, carbamazepine, ciclosporin, colchicine, disopyramide, efavirenz, eletriptan, eplerenone, itraconazone, ivabradine, methylprednisolone, midazolam, omeprazole, phenytoin, pimozide, repaglinide, ritabutin, rifamycins, ritonavir, sildenafil, simvastatin, sirolimus, tacrolimus, tadalafil, theophylline, tipranavir, tolterodine, verapamil, warfarin and zidovudine)

发起方

ottingham University